alzheimers_brain

Alzheimer’s drug failure sends Lundbeck’s shares crashing

pharmafile | September 23, 2016 | News story | Medical Communications, Research and Development Alzheimer's, Lundbeck, cultural failings 

Lundbeck’s experimental idalopirdine has failed to meet its primary endpoint in its first Phase III trial in the treatment of Alzheimer’s.

The company saw its shares fall by 17% as a result of the news, its biggest drop in four years. The study could not reproduce the promising findings of earlier studies, with the drug failing to improve symptoms of the disease according to the Alzheimer’s Disease Assessment Scale-cognitive (ADAS-cog).

Idalopirdine promotes a chemical the brain uses to process thought by blocking a cell receptor called 5-HT6. The Copenhagen-based company has two additional late-stage studies ongoing, with results expected early next year.

Advertisement

Matt Fellows

Related Content

brain-770044_960_720

Lilly’s drug for early Alzheimer’s shows promising results

Eli Lilly (Lilly) has announced positive new data from the long-term extension of its phase …

Eli Lilly’s Kisunla approved by FDA for Alzheimer’s treatment

Eli Lilly has announced that the US Food and Drug Administration (FDA) has approved Kisunla …

robina-weermeijer-ihfopazzjhm-unsplash_5

FDA accepts Eisai’s Leqembi sBLA for early AD treatment

Eisai and Biogen have announced that the US Food and Drug Administration (FDA) has accepted …

The Gateway to Local Adoption Series

Latest content